This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
cannabis: Archive
Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?
by Zacks Equity Research
ACB's global medical cannabis momentum stays strong, but near-term regulatory headwinds might have limited Q1 revenue upside.
CGCPositive Net Change TLRYPositive Net Change ACBPositive Net Change
cannabis medical
Do Options Traders Know Something About Aurora Cannabis Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to ACB stock based on the movements in the options market lately.
ACBPositive Net Change
cannabis medical medical-devices
GRWG Inks Distribution Agreement With V1 Solutions to Expand Globally
by Zacks Equity Research
GrowGeneration signs V1 Solutions to drive EU distribution and enters Costa Rica, entering deeper into global cannabis markets.
AGIPositive Net Change SSRMPositive Net Change HWKNPositive Net Change GRWGPositive Net Change
basic-materials cannabis
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook
by Zacks Equity Research
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
JAZZPositive Net Change PBYINo Net Change NTLAPositive Net Change
biotechs cannabis earnings marijuana medical pharmaceuticals
IIPR's Q1 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
IIPR's Q1 2025 results may be impacted by property repossessions/sales, rent deferrals and partial tenant payments.
IIPRPositive Net Change LAMRPositive Net Change EPRPositive Net Change
cannabis finance marijuana reit
Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings
by Sundeep Ganoria
Investors will likely focus on the sales performance of Jazz Pharmaceuticals' key neuroscience drugs, Xywav and Rylaze, when it reports Q1 results next week.
JAZZPositive Net Change AMRXPositive Net Change
biotechs cancer cannabis earnings-preview marijuana medical
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play?
by Sundeep Ganoria
Both JAZZ and HRMY expect sales from neuroscience products to grow in 2025.
JAZZPositive Net Change HRMYPositive Net Change
biotechs cannabis marijuana marijuana-stocks medical pharmaceuticals
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell?
by Sundeep Ganoria
We advise investors to use the price dip in JAZZ stock as a buying opportunity despite the dynamic shifts in the regulatory landscape.
JAZZPositive Net Change EBSPositive Net Change
biotechs cannabis medical pharmaceuticals
Aurora Cannabis Rides the Global Legalization Wave: Should You Invest?
by Urmimala Biswas
ACB capitalizes on the rapidly evolving medical cannabis landscape, leveraging its EU GMP-certified manufacturing facilities, advanced genetics and deep regulatory knowledge.
CGCPositive Net Change ACBPositive Net Change OGIPositive Net Change
cannabis healthcare marijuana marijuana-stocks medical
IIPR's Q4 Earnings Coming Up: Key Factors to Impact the Stock
by Zacks Equity Research
Innovative Industrial's Q4 performance is likely to have been affected by a decline in contractual rent and property management fees and elevated expenses.
RHPPositive Net Change IIPRPositive Net Change PKPositive Net Change
cannabis finance marijuana reit
Is IIPR Stock a Buy, Hold or Sell After Its 49% Plunge in 3 Months?
by Moumita C. Chattopadhyay
With a volatile cannabis market and tenant risks, is IIPR's high yield sustainable, or will challenges overshadow its growth?
PLDPositive Net Change TRNOPositive Net Change IIPRPositive Net Change
cannabis finance marijuana marijuana-stocks reit
GrowGeneration Earnings Miss Estimates in Q3, Revenues Dip Y/Y
by Zacks Equity Research
GRWG expects revenues between $190 million and $195 million for 2024.
BGPositive Net Change RKDANegative Net Change GRWGPositive Net Change WFGPositive Net Change
basic-materials cannabis earnings
Pre-Markets Soar after Trump Wins U.S. Presidential Election
by Zacks Equity Research
Pre-Markets Soar after Trump Wins U.S. Presidential Election
QCOMPositive Net Change TMPositive Net Change GILDNegative Net Change TSLAPositive Net Change TRIPPositive Net Change ACBPositive Net Change COINPositive Net Change ARKBPositive Net Change
auto-tires-trucks biotechs bitcoin blockchain cannabis cryptocurrency etfs semiconductor
Factors to Impact Innovative Industrial's (IIPR) Q2 Earnings
by Zacks Equity Research
With the cannabis industry gaining prominence, Innovative Industrial's (IIPR) investments in such properties are likely to have aided its Q2 performance, though high expenses might have played a spoilsport.
SPGPositive Net Change APLEPositive Net Change IIPRPositive Net Change
cannabis finance reit
Should You Buy Canopy Growth (CGC) Ahead of Q4 Earnings?
by Moumi Mondal
Canopy Growth's (CGC) rightsized cannabis-focused business is a major foundation for growth.
INGNPositive Net Change HQYPositive Net Change CGCPositive Net Change HIMSPositive Net Change
cannabis medical medical-devices
4 Agriculture - Products Stocks to Watch in a Thriving Industry
by Madhurima Das
The Agriculture - Products industry is set to gain from solid demand. Stocks like WestFraser (WFG), CalMaine Foods (CALM), Andersons (ANDE) and Hydrofarm (HYFM) are poised to ride on this positive trend.
WFGPositive Net Change ANDEPositive Net Change CALMPositive Net Change HYFMPositive Net Change
agriculture basic-materials cannabis
Factors to Impact Innovative Industrial's (IIPR) Q1 Earnings
by Zacks Equity Research
With the cannabis industry gaining prominence, Innovative Industrial's (IIPR) investments in such properties are likely to have aided its Q1 performance, though high expenses might have played a spoilsport.
MPWPositive Net Change IIPRPositive Net Change PKSTPositive Net Change
cannabis earnings finance reit
New Strong Buy Stocks for April 2nd
by Zacks Equity Research
CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.
SIGAPositive Net Change CPGPositive Net Change CXDOPositive Net Change HITIPositive Net Change CTKBPositive Net Change
cannabis cell-therapy cloud-computing medical oil-energy
GrowGeneration (GRWG) Q4 Earnings Miss, Revenues Dip Y/Y
by Zacks Equity Research
GrowGeneration's (GRWG) 2023 top line falls y/y despite improvements in the product mix.
ECLPositive Net Change CRSPositive Net Change HWKNPositive Net Change GRWGPositive Net Change
basic-materials cannabis earnings
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
by Zacks Equity Research
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
JAZZPositive Net Change ACETPositive Net Change PBYINo Net Change ADMAPositive Net Change
cannabis earnings medical
Pot Stocks: Values or Traps?
by Tracey Ryniec
Pot stocks used to be hot but many have plunged over the last 2 years. Are there deals?
STZPositive Net Change JAZZPositive Net Change IIPRPositive Net Change CGCPositive Net Change TLRYPositive Net Change
cannabis
GrowGeneration (GRWG) Q3 Earnings Miss, Revenues Dip Y/Y
by Zacks Equity Research
GrowGeneration (GRWG) witnesses year-over-year decline in retail revenues, e-commerce revenues and non-retail operations in Q3.
ANDEPositive Net Change CRSPositive Net Change USAPPositive Net Change GRWGPositive Net Change
basic-materials cannabis earnings
Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View
by Zacks Equity Research
Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.
JAZZPositive Net Change BHVNPositive Net Change CDMOPositive Net Change APLSPositive Net Change
cannabis earnings medical
Factors to Impact Innovative Industrial's (IIPR) Q3 Earnings
by Zacks Equity Research
With the cannabis industry gaining prominence, Innovative Industrial's (IIPR) investments in such properties are likely to have aided its Q3 performance, though high expenses might have played a spoilsport.
VTRNegative Net Change DEAPositive Net Change IIPRPositive Net Change
cannabis earnings finance reit
Cannabis Stocks & ETFs: Can the Recent Surge Continue?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
TLRYPositive Net Change CNBSPositive Net Change GTBIFNegative Net Change CURLFPositive Net Change
cannabis etfs